Innovative approaches to anti-arrhythmic drug therapy

Nature Reviews Drug Discovery

Volumn 5, Issue 12, 2006, Pages 1034-1049

  Nattel, Stanley ^a   Carlsson, Leif ^b  

^a MONTREAL HEART INSTITUTE   (Canada)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; 1,3 DIHYDRO 5 (2 FLUOROPHENYL) 3 (1H INDOL 3 YLMETHYL) 1 METHYL 2H 1,4 BENZODIAZEPIN 2 ONE; 2' (4 METHOXYPHENYLACETAMIDOMETHYL) N [2 (3 PYRIDYL)ETHYL] 2 BIPHENYLCARBOXAMIDE; 4 [3 (4 BENZYL 1 PIPERIDINYL)PROPIONYL] 2,3,4,5 TETRAHYDRO 7 METHOXY 1,4 BENZOTHIAZEPINE; AMIODARONE; ANTIARRHYTHMIC AGENT; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; AZD 7009; AZIMILIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARDIOVASCULAR AGENT; CLAMIKALANT; DOFETILIDE; DRONEDARONE; ENDOTHELIN RECEPTOR ANTAGONIST; FENOFENADINE; HMR 1566; HMR1566; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IVABRADINE; MIBEFRADIL; NIP 151; NS 1643; NS1643; QUINIDINE; ROTIGAPTIDE; RSD 1235; SOTALOL; SSR 149744C; TEDISAMIL; UNINDEXED DRUG; XEN D 0101;

ADOPTIVE IMMUNOTHERAPY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DISEASE EXACERBATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; FATALITY; GENE THERAPY; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART BEAT; HEART MUSCLE ISCHEMIA; HEART PROARRHYTHMIA; HEART RHYTHM; HEART VENTRICLE FIBRILLATION; HUMAN; LONG QT SYNDROME; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SYMPTOM;

EID: 33751527644     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2112     Document Type: Review

References (178)

1. Wolf, P. A., Mitchell, J. B., Baker, C. S., Kannel, W. B. & D'Agostino, R. B. Impact of atrial fibrillation on mortality, stroke, and medical costs. Arch. Intern. Med. 158, 229-234 (1998).
2. van den Berg, M. P., van Gelder, I. C. & van Veldhuisen, D. J. Impact of atrial fibrillation on mortality in patients with chronic heart failure. Eur. J. Heart Fail. 4, 571-575 (2002).
3. Nattel, S. New ideas about atrial fibrillation 50 years on. Nature 415, 219-226 (2002).
4. Miyasaka, Y. et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 114, 119-125 (2006).
5. Kimura, K., Minematsu, K., Yamaguchi, T. & Japan Multicenter Stroke Investigators' Collaboration (J-MUSIC). Atrial fibrillation as a predictive factor for severe stroke and early death in 15, 831 patients with acute ischaemic stroke. J. Neurol. Neurosurg. Psychiatry 76, 679-683 (2005).
6. Guerra, P. G. et al. Is there a future for antiarrhythmic drug therapy? Drugs 56, 767-781 (1998).
7. The Sicilian Gambit. A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. Circulation 84, 1831-1851 (1991).
8. Nattel, S. The molecular and ionic specificity of antiarrhythmic drug actions. J. Cardiovasc. Electrophysiol. 10, 272-282 (1999).
9. Wible, B. A. et al. HERG-Lite: A novel comprehensive high-throughput screen for drug-induced hERG risk. J. Pharmacol. Toxicol. Methods 52, 136-145 (2005).
10. Roden, D. M. Taking the 'idio' out of 'idiosyncratic': Predicting torsades de pointes. Pacing Clin. Electrophysiol. 21, 1029-1034 (1998).
11. Marban, E. Cardiac channelopathies. Nature 415, 213-218 (2002).
12. + current similar to Kv 1.5 cloned channel currents. Circ. Res. 73, 1061-1076 (1993).
13. + current in cultured adult human atrial myocytes. Circ. Res. 80, 572-579 (1997).
14. + current in human ventricular myocytes. Circ. Res. 78, 689-696 (1996).
15. Han, W., Zhang, L., Schram, G. & Nattel, S. Properties of potassium currents in human cardiac Purkinje cells of failing human hearts. Am. J. Physiol. (Heart & Circ. Physiol.) 283, H2495-H2503 (2002).
16. Peukert, S. et al. Pharmacophore-based search, synthesis, and biological evaluation of anthranilic amides as novel blockers of the Kv 1.5 channel. Bioorg. Med. Chem. Lett. 14, 2823-2827 (2004).
17. Blaauw, Y. et al. 'Early' class III drugs for the treatment of atrial fibrillation: Efficacy and atrial selectivity of AVE0118 in remodeled atria of the goat. Circulation 110, 1717-1724 (2004).
18. Kur/Kv 1.5 blocker in dogs. Heart Rhythm 2 (Suppl.), S180 (2005).
19. Kur/Kv 1.5 blocker in dogs with atrial tachycardia remodeling. Heart Rhythm 3, S183 (2006).
20. Courtemanche, M., Ramirez, R. J. & Nattel, S. Ionic targets for drug therapy and atrial fibrillation-induced electrical remodeling: Insights from a mathematical model. Cardiovasc. Res. 42, 477-489 (1999).
21. Wettwer, E. et al. Role of IKur in controlling action potential shape and contractility in the human atrium: Influence of chronic atrial fibrillation. Circulation 110, 2299-2306 (2004).
22. + channels by endothelium-derived relaxing factors. Clin. Exp. Pharmacol. Physiol. 26, 180-184 (1999).
23. Chung, S., Saal, D. B. & Kaczmarek, L. K. Elimination of potassium channel expression by antisense oligonucleotides in a pituitary cell line. Proc. Natl Acad. Sci. USA 92, 5955-5959 (1995).
24. Philipson, L. H. et al. Sequence and functional expression in Xenopus oocytes of a human insulinoma and islet potassium channel. Proc. Natl Acad. Sci. USA 88, 53-57 (1991).
25. Ehrlich, J. R. et al. Characterization of a hyperpolarization-activated time-dependent potassium current in canine cardiomyocytes from pulmonary vein myocardial sleeves and left atrium. J. Physiol. 557, 583-597 (2004).
26. Dobrev, D. et al. The G protein-gated potassium current I(K, ACh) is constitutively active in patients with chronic atrial fibrillation. Circulation 112, 3697-3706 (2005).
27. Cha, T. J., Ehrlich, J. R., Chartier, D., Xiao, L. & Nattel, S. Kir3-based inward rectifier potassium current: Potential role in atrial tachycardia remodeling effects on atrial repolarization and arrhythmias. Circulation 113, 1730-1737 (2006).
28. Matsuda, T. et al. Blockade by NIP-142, an antiarrhythmic agent, of carbachol-induced atrial action potential shortening and GIRK1/4 channel. J. Pharmacol. Sci. 101, 303-310 (2006).
29. Kneller, J. et al. Mechanisms of AF termination by pure sodium channel blockade in an ionically-realistic mathematical model. Circ. Res. 96, e48-e57 (2005).
30. Nattel, S., De Blasio, E., Wang, W.-Q. & Beatch, G. N. RSD1235: A novel antiarrhythmic agent with a unique electrophysiological profile that terminates AF in dogs (abstract). Eur. Heart J. 22 (Suppl.), 448 (2001).
31. Roy, D. et al. CRAFT Investigators. A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation. J. Am. Coll. Cardiol. 44, 2355-2361 (2004).
32. Fedida, D. et al. The mechanism of atrial antiarrhythmic action of RSD1235. J. Cardiovasc. Electrophysiol. 16, 1227-1238 (2005).
33. Carlsson, L., Chartier, D. & Nattel, S. Characterization of the in vivo and in vitro electrophysiological effects of the novel antiarrhythmic agent AZD7009 in atrial and ventricular tissue of the dog. J. Cardiovasc. Pharmacol. 47, 123-132 (2006).
34. Page, R. L. & Roden, D. M. Drug therapy for atrial fibrillation: Where do we go from here? Nature Rev. Drug Discov. 4, 899-910 (2005).
35. Elharrar, V. & Zipes, D. P. Cardiac electrophysiologic alterations during myocardial ischemia. Am. J. Physiol. 233, H329-H345 (1977).
36. Janse, M. J. & Wit, A. L. Electrophysiological mechanisms of ventricular arrhythmias resulting from myocardial ischemia and infarction. Physiol. Rev. 69, 1049-1169 (1989).
37. Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. N. Engl. J. Med. 321, 406-412 (1989).
38. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. The Cardiac Arrhythmia Suppression Trial II Investigators. N. Engl. J. Med. 327, 227-233 (1992).
39. Zareba, W. Implantable cardioverter defibrillator therapy in postinfarction patients. Curr. Opin. Cardiol. 19, 619-624 (2004).
40. Nattel, S. & Waters, D. What is an antiarrhythmic drug? From clinical trials to fundamental concepts. Am. J. Cardiol. 66, 96-99 (1990).
41. + channels in cardiac muscle. Nature 305, 147-148 (1983).
42. Gross, G. J. The role of mitochondrial KATP channels in cardioprotection. Basic Res. Cardiol. 95, 280-284 (2000).
43. Gogelein, H., Hartung, J., Englert, H. C. & Scholkens, B. A. HMR 1883, a novel cardioselective inhibitor of the ATP-sensitive potassium channel. Part I: Effects on cardiomyocytes, coronary flow and pancreatic β-cells. J. Pharmacol. Exp. Ther. 286, 1453-1464 (1998).
44. Li, R. A., Leppo, M., Miki, T., Seino, S. & Marban, E. Molecular basis of electrocardiographic ST-segment elevation. Circ. Res. 87, 837-839 (2000).
45. Billman, G. E., Englert, H. C. & Scholkens, B. A. HMR 1883, a novel cardioselective inhibitor of the ATP-sensitive potassium channel. Part II: Effects on susceptibility to ventricular fibrillation induced by myocardial ischemia in conscious dogs. J. Pharmacol. Exp. Ther. 286, 1465-1473 (1998).
46. Brugada, J., Brugada, R. & Brugada, P. Right bundle-branch block and ST-segment elevation in leads V1 through V3: A marker for sudden death in patients without demonstrable structural heart disease. Circulation 97, 457-460 (1998).
47. Elharrar, V., Gaum, W. E. & Zipes, D. P. Effect of drugs on conduction delay and incidence of ventricular arrhythmias induced by acute coronary occlusion in dogs. Am. J. Cardiol. 39, 544-549 (1977).
48. Brugada, R. et al. Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle branch block but structurally normal hearts. Circulation 101, 510-515 (2000).
49. Di Diego, J. M., Fish, J. M. & Antzelevitch, C. Brugada syndrome and ischemia-induced ST-segment elevation. Similarities and differences. J. Electrocardiol. 38 (Suppl. 4), 14-17 (2005).
50. Brown, H. & Difrancesco, D. Voltage-clamp investigations of membrane currents underlying pacemaker activity in rabbit sino-atrial node. J. Physiol. 308, 331-351 (1980).
51. Stieber, J., Hofmann, F. & Ludwig, A. Pacemaker channels and sinus node arrhythmia. Trends Cardiovasc. Med. 14, 23-28 (2004).
52. Saint, D. A. Pacemaking in the heart: The interplay of ionic currents. Clin. Exp. Pharmacol. Physiol. 25, 841-846 (1998).
53. Difrancesco, D. Funny channels in the control of cardiac rhythm and mode of action of selective blockers. Pharmacol. Res. 53, 399-406 (2006).
54. Hsia, H. H. & Marchlinski, F. E. Electrophysiology studies in patients with dilated cardiomyopathies. Card. Electrophysiol. Rev. 6, 472-481 (2002).
55. Nazir, S. A. & Lab, M. J. Mechanoelectric feedback and atrial arrhythmias. Cardiovasc. Res. 32, 52-61 (1996).
56. Lab, M. J. Mechanoelectric feedback (transduction) in heart: Concepts and implications. Cardiovasc. Res. 32, 3-14 (1996).
57. Henry, W. L. et al. Relation between echocardiographically determined left atrial size and atrial fibrillation. Circulation 53, 273-279 (1976).
58. Vaziri, S. M., Larsson, M. G., Benjamin, E. J. & Levy, D. Echocardiographic predictors of nonrheumatic atrial fibrillation: The Framingham Heart Study. Circulation 89, 724-730 (1994).
59. Zou, R., Kneller, J., Leon, L. J. & Nattel, S. Substrate size as a determinant of fibrillatory activity maintenance in a mathematical model of canine atrium. Am. J. Physiol. (Heart Circ. Physiol.) 289, H1002-H1012 (2005).
60. Hu, H. & Sachs, F. Stretch-activated ion channels in the heart. J. Mol. Cell. Cardiol. 29, 1511-1523 (1997).
61. Suchyna, T. M. et al. The identification of a peptide toxin from Grammostola spatulata spider venom that blocks cation-selective stretch-activated channels. J. Gen. Physiol. 115, 583-598 (2000).
62. Gottlieb, P. A., Suchyna, T. M., Ostrow, L. W. & Sachs, F. Mechanosensitive ion channels as drug targets. Curr. Drug Targets-CNS Neurol. Disord. 4, 287-295 (2004).
63. Bode, F., Sachs, F. & Franz, M. R. Tarantula peptide inhibits atrial fibrillation. Nature 409, 35-36 (2001). A key description of the role of tissue stretch in atrial fibrillation and of the potential of stretch-channel inhibitors to suppress the arrhythmia.
64. Suchyna, T. M. et al. Bilayer-dependent inhibition of mechanosensitive channels by neuroactive peptide enantiomers. Nature 430, 235-240 (2004).
65. Ninio, D. M., Murphy, K. J., Howe, P. R. & Saint, D. A. Dietary fish oil protects against stretch-induced vulnerability to atrial fibrillation in a rabbit model. J. Cardiovasc. Electrophysiol. 16, 1-6 (2005).
66. Scoote, M. & Williams, A. J. Myocardial calcium signalling and arrhythmia pathogenesis. Biochem. Biophys. Res. Comm. 322, 1286-1309 (2004).
67. Marx, S. O. et al. PKA phosphorylation dissociates FKBP 12.6 from the calcium release channel (ryanodine receptor): Defective regulation in failing hearts. Cell 101, 365-376 (2000).
68. Lehnart, S. E., Wehrens, X. H. T. & Marks, A. R. Calstabin deficiency, ryanodine receptors, and sudden death. Biochem. Biophys. Res. Comm. 322, 1267-1279 (2004).
69. Doggrell, S. A. Stabilisation of calstabin2 - a new approach in sudden cardiac death. Expert Opin. Ther. Targets 9, 955-962 (2005).
70. Yano, M. et al. FKBP12. 6 mediated stabilization of calcium release channel (ryanodine receptors) as a novel therapeutic strategy against heart failure. Circulation 107, 477-484 (2003).
71. Wehrens, X. H. et al. Protection from cardiac arrhythmia through ryanodine-receptor stabilizing protein calstabin2. Science 304, 292-296 (2004).
72. Kumagai, K., Nakashima, H., Gondo, N. & Saku, K. Antiarrhythmic effects of JVT-519, a novel cardiprotective drug, on atrial fibrillation/flutter in a canine sterile pericarditis model. J. Cardiovasc. Electrophysiol. 14, 880-884 (2003).
73. Vest, J. A. et al. Defective cardiac ryanodine receptor regulation during atrial fibrillation. Circulation 111, 2025-2032 (2005).
74. Anderson, C. L. et al. Most LQT2 mutations reduce Kv11.1 (hERG) current by a class 2 (trafficking-deficient) mechanism. Circulation 113, 365-373 (2006).
75. Dzura, I., Wu, Y., Colbram, R. J., Balser, J. R. & Anderson, M. E. Calmodulin kinase determines calcium-dependent facilitation of L-type calcium channels. Nature Cell Biol. 2, 173-177 (2000).
76. Anderson, M. E. et al. Brugada syndrome. Report from the second consensus conference. Heart Rhythm 2, 429-440 (2005).
77. Gutstein, D. E. et al. Conduction slowing and sudden arrhythmic death in mice with cardiac-restricted inactivation of connexin43. Circ. Res. 88, 333-339 (2001).
78. De Groot, J. T. & Coronel, R. Acute ischemia-induced gap junctional uncoupling and arrhythmogenesis. Cardiovasc. Res. 62, 323-334 (2004).
79. Akar, F. G., Spragg, D. D., Tunin, R. S., Kass, D. A. & Tomaselli, G. F. Mechanisms underlying conduction slowing and arrhythmogenesis in nonischemic dilated cardiomyopathy. Circ. Res. 95, 717-725 (2004).
80. Firouzi, M. et al. Association of human connexin40 gene polymorphisms with atrial vulnerability as a risk factor for idiopathic atrial fibrillation. Circ. Res. 95, e29-e33 (2004).
81. van der Velden, H. M. et al. Altered pattern of connexin40 distribution in persistent atrial fibrillation in the goat. J. Cardiovasc. Electrophysiol. 9, 596-607 (1998).
82. Shaw, R. M. & Rudy, Y. Ionic mechanisms of propagation in cardiac tissue. Roles of the sodium and L-type calcium currents during reduced excitability and decreased gap junction coupling. Circ. Res. 81, 727-741 (1997).
83. Aonuma, S. et al. Studies on heart. XIX. Isolation of an atrial peptide that improves the rhythmicity of cultured myocardial cell clusters. Chem. Pharm. Bull. (Tokyo) 28, 3332-3339 (1980).
84. Kjolbye, A. L., Knudsen, C. B., Jepsen, T., Larsen, B. D. & Petersen, J. S. Pharmacological characterization of the new stable antiarrhythmic peptide analog Ac-D-Pro-D-Hyp-Gly-D-Ala-Gly-NH2 (ZP123): In vivo and in vitro studies. J. Pharmacol. Exp. Ther. 306, 1191-1199 (2003).
85. Xing, D. et al. ZP123 increases gap junctional conductance and prevents reentrant ventricular tachycardia during myocardial ischemia in open chest dogs. J. Cardiovasc. Electrophysiol. 14, 510-520 (2003).
86. Haugan, K. et al. The antiarrhythmic peptide analog ZP123 prevents atrial conduction slowing during metabolic stress. J. Cardiovasc. Electrophysiol. 16, 537-545 (2005).
87. Kääb, S. & Schulze-Bahr, E. Susceptibility genes and modifiers for cardiac arrhythmias. Cardiovasc. Res. 67, 397-413 (2005).
88. Bezzina, C. R. et al. Common sodium channel promoter haplotype in asian subjects underlies variability in cardiac conduction. Circulation 113, 338-344 (2006).
89. Priori, S. G. Inherited arrhythmogenic diseases. The complexity beyond monogenic disorders. Circ. Res. 94, 140-145 (2004).
90. Antzelevitch, C., Brugada, P., Brugada, J. & Brugada, R. Brugada syndrome: From cell to bedside. Curr. Probl. Cardiol. 30, 9-54 (2005).
91. Xu, X. et al. Increasing I(Ks) corrects abnormal reolarization in rabbit models of acquired LQT2 and ventricular hypertrophy. Am. J. Physiol. Heart Circ. Physiol. 283, H664-H670 (2002).
92. Casis, O., Olesen, S. P. & Sanguinetti, M. C. Mechanism of action of a novel human ether-a-go-go-related gene channel activator. Mol. Pharmacol. 69, 658-665 (2006).
93. Han, W., Wang, Z. & Nattel, S. Slow delayed rectifier current and repolarization in canine cardiac Purkinje cells. Am. J. Physiol. (Heart Circ. Physiol.) 280, H1075-H1080 (2001).
94. Zhou, Z., Gong, Q., Epstein, M. L. & January, C. T. HERG channel dysfunction in human long QT syndrome: Intracellular transport and functional defects. J. Biol. Chem. 273, 21061-21066 (1998).
95. Robertson, G. A. & January, C. T. HERG trafficking and pharmacological rescue of LQTS-2 mutant channels. Handb. Exp. Pharmacol. 171, 349-355 (2006).
96. Delisle, B. P., Anson, B. D., Rajamani, S. & January, C. T. Biology of cardiac arrhythmias: Ion channel protein trafficking. Circ. Res. 94, 1418-1428 (2004).
97. + channel long QT2 mutations: Human ether-a-go-go-related gene rescue without block. Circulation 105, 2830-2835 (2002).
98. Gong, Q., Anderson, C. L., January, C. T. & Zhou, Z. Pharmacological rescue of trafficking defective HERG channels formed by coassembly of wild-type and long QT mutant N470D subunits. Am. J. Physiol. Heart Circ. Physiol. 287, H652-H658 (2004).
99. Brugada, R. et al. Sudden death associated with short-QT syndrome linked to mutations in HERG. Circulation 109, 30-35 (2004).
100. Bellocq, C. et al. Mutation in the KCNQ1 gene leading to the short QT-interval syndrome. Circulation 109, 2394-2397 (2004).
101. Priori, S. G. et al. A novel form of short QT syndrome (SQT3) is caused by a mutation in the KCNJ2 gene. Circ. Res. 96, 800-807 (2005).
102. Tamargo, J., Caballero, R., Gomez, R., Valenzuela, C. & Delpon, E. Pharmacology of cardiac potassium channels. Cardiovasc. Res. 62, 9-33 (2004).
103. Thomas, G. P., Gerlach, U. & Antzelevitch. C. HMR 1556, a potent and selective blocker of slowly activating delayed rectifier potassium current. J. Cardiovasc. Pharmacol. 41, 140-147 (2003).
104. Butcher, J. W. et al. Novel 5-cyclopropyl-1, 4-benzodiazepin-2-ones as potent and selective I(Ks)-blocking class III antiarrhythmic agents. Bioorg. Med. Chem. Lett. 13, 1165-1168 (2003).
105. Antzelevitch, C. et al. Brugada syndrome: Report of the second consensus conference. Heart Rhythm 2, 429-440 (2005).
106. Marks, A. R., Priori, S., Memmi, M., Kontula, K. & Laitinen, P. J. Involvement of the cardiac ryanodine receptor/calcium release channel in catecholaminergic polymorphic ventricular tachycardia. J. Cell. Physiol. 190, 1-6 (2002).
107. Francis, J., Sankar, V., Nair, V. K. & Priori, S. G. Catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm 2, 550-554 (2005).
108. Nam, G. B., Burashnikov, A. & Antzelevitch, C. Cellular mechanisms underlying the development of catecholaminergic ventricular tachycardia. Circulation 111, 2727-2733 (2005).
109. 2+ activation are common defects of RyR2 mutations linked to ventricular tachycardia and sudden death. Circ. Res. 97, 1173-1181 (2005).
110. Donahue, J. K., Kikuchi, K. & Sasano, T. Gene therapy for cardiac arrhythmias. Trends Cardiovasc. Med. 15, 219-224 (2005).
111. Rosen, M. R. Biological pacemaking: In our lifetime? Heart Rhythm 2, 418-428 (2005).
112. Murata, M., Cingolani, E., McDonald, A. D., Donahue, J. K. & Marbán, E. Creation of a genetic calcium channel blocker by targeted Gem gene transfer in the heart. Circ. Res. 95, 398-405 (2004).
113. Johns, D. C. et al. Adenovirus-mediated expression of a voltage-gated potassium channel in vitro (rat cardiac myocytes) and in vivo (rat liver). A novel strategy for modifying excitability. J. Clin. Invest. 96, 1152-1158 (1995).
114. Nuss, B., Marbán, E. & Johns, D. Overexpression of a human potassium channel suppresses cardiac hyperexcitability in rabbit ventricular myocytes. J. Clin. Invest. 103, 889-896 (1999).
115. Ennis, I., Li, R., Murphy, A. & Nuss, H. Dual gene therapy with SERCA1 and Kir 2.1 abbreviates excitation without suppressing contractility. J. Clin. Invest. 109, 393-400 (2002).
116. Kodirov, S., Brunner, M., Busconi, L. & Koren, G. Long-term restitution of 4-aminopyridine-sensitive currents in Kv1DN ventricular myocytes using adeno-associated virus-mediated delivery of Kv 1.5. FEBS Lett. 550, 74-78 (2003).
117. Kikuchi, K., McDonald, A. D., Sasano, T. & Donahue, J. K. Targeted modification of atrial electrophysiology by homogenous transmural atrial gene transfer. Circulation 111, 264-270 (2005).
118. Fabiato, A. & Fabiato, F. Contractions induced by a calcium-triggered release of calcium from the sarcoplasmic reticulum of single skinned cardiac cells. J. Physiol. 249, 469-495 (1975).
119. Bers, D. M. Cardiac excitation-contraction coupling. Nature 415, 198-205 (2002).
120. Lehnart, S. E., Wehrens, X. H. T. & Marks, A. R. Calstabin deficiency, ryanodine receptors, and sudden death. Biochem. Biophys. Res. Comm. 322, 1267-1279 (2004).
121. Marx, S. O. et al. PKA phosphorylation dissociates FKBP12. 6 from the calcium release channel (ryanodine receptor): Defective regulation in failing hearts. Cell 101, 365-376 (2000).
122. 2+ leak in heart failure. Circ. Res. 97, 1314-1322 (2005).
123. Scoote, M. & Williams, A. J. Myocardial calcium signalling and arrhythmia pathogenesis. Biochem. Biophys. Res. Comm. 322, 1286-1309 (2004).
124. Aonuma, S. et al. Studies on heart. XIX. Isolation of an atrial peptide that improves the rhythmicity of cultured myocardial cell clusters. Chem. Pharm. Bull. (Tokyo). 28, 3332-3339 (1980).
125. Aonuma, S., Kohama. Y., Makino, T. & Fujisawa, T. Studies of heart. XXI. Amino acid sequence of antiarrhythmic peptide (AAP) isolated from atria. J. Pharmacobiodyn. 5, 40-48 (1982).
126. Argentieri, T., Cantor, E. & Wiggins, J. R. Antiarrhythmic peptide has no direct cardiac actions. Experientia 45, 737-738 (1989).
127. Dhein, S. et al. A new synthetic antiarrhythmic peptide reduces dispersion of epicardial activation recovery interval and diminishes alterations of epicardial activation patterns induced by regional ischemia. Naunyn-Schmiedeberg's Arch. Pharmacol. 350, 174-184 (1994).
128. Kohama, Y., Okimoto, N., Mimura, T., Fukaya, C., Watanabe, M., Yokoyama, K. A new antiarrhythmic peptide, N-3-(4-hydroxyphenyl)propionyl-Pro-Hyp-Gl y-Ala-Gly. Chem. Pharm. Bull. 35, 3928-3930 (1987).
129. Dhein, S. & Tudyka, T. Therapeutic potential of antiarrhythmic peptides. Cellular coupling as a new antiarrhythmic target. Drugs. 49, 851-855 (1995).
130. Weng, S., Lauven, M., Schaeffer, T., Polontchouk, L., Grover, R., Dhein, S. Pharmacological modification of gap junction coupling by an antiarrhythmic peptide via protein kinase C activation. FASEB J. 16, 1114-1116 (2002).
131. Grover, R. & Dhein, S. Structure-activity relationships of novel peptides related to the antiarrhythmic peptide AAP10 which reduce the dispersion of epicardial action potential duration. Peptides 22, 1011-1021 (2001).
132. Kjølbye, A. L., Knudsen, C. B., Jepsen, T., Larsen, B. D. & Petersen, J. S. Pharmacological characterization of the new stable antiarrhythmic peptide analog Ac-D-Pro-D-Hyp-Gly-D-Ala-Gly-NH2 (ZP123): In vivo and in vitro studies. J. Pharmacol. Exp. Ther. 306, 1191-1199 (2003).
133. Xing, D. et al. ZP123 increases gap junctional conductance and prevents reentrant ventricular tachycardia during myocardial ischemia in open chest dogs. J. Cardiovasc. Electrophysiol. 14, 510-520 (2003).
134. Eloff, B. C., Gilat, E., Wan, X. & Rosenbaum D. S. Pharmacological modulation of cardiac gap junctions to enhance cardiac conduction. Evidence supporting a novel target for antiarrhythmic therapy. Circulation 108, 3157-3163 (2003).
135. Haugan, K. et al. The antiarrhythmic peptide analog ZP123 prevents atrial conduction slowing during metabolic stress. J. Cardiovasc. Electrophysiol. 16, 537-545 (2005).
136. Xing, D., Kjølbye, A. L., Petersen, J. S. & Martins, J. B. Pharmacological stimulation of cardiac gap junction coupling does not affect ischemia-induced focal ventricular tachycardia or triggered activity in dogs. Am. J. Physiol. Heart Circ. Physiol. 288, H511-H516 (2005).
137. Hamman, J. H., Enslin, G. M. & Kotzé, A. F. Oral delivery of peptide drugs. Barriers and developments. Biodrugs 19, 165-177 (2005).
138. Nattel, S., Maguy, A., Le Bouter, S. & Yeh, Y. H. Arrhythmogenic ion-channel remodeling in the heart. Physiol. Rev. (in the press).
139. Nattel, S., Shiroshita-Takeshita, A., Cardin, S. & Pelletier, P. Mechanisms of atrial remodeling and clinical relevance. Curr. Opin. Cardiol. 20, 21-25 (2005).
140. Li, D., Fareh, S., Leung, T. K. & Nattel, S. Promotion of atrial fibrillation by heart failure in dogs: Atrial remodeling of a different sort. Circulation 100, 87-95 (1999).
141. Cha, T. J. et al. Dissociation between ionic remodeling and ability to sustain atrial fibrillation during recovery from experimental congestive heart failure. Circulation 109, 412-418 (2004).
142. Li, D. et al. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 104, 2608-2614 (2001).
143. Cardin, S. et al. Evolution of the atrial fibrillation substrate in experimental congestive heart failure: Angiotensin-dependent and independent pathways. Cardiovasc. Res. 60, 315-325 (2003).
144. Kumagai, K. et al: Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J. Am. Coll. Cardiol. 41, 2197-2204 (2003).
145. Healey, J. S. et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: A meta-analysis. J. Am. Coll. Cardiol. 45, 1832-1839 (2005).
146. Carnes, C. A. et al: Ascorbate attenuates atrial pacing-induced peroxynitrite formation and electrical remodeling and decreases the incidence of postoperative atrial fibrillation. Circ. Res. 89, E32-E38 (2001).
147. Kim, Y. M. et al. A myocardial Nox2 containing NAD(P)H oxidase contributes to oxidative stress in human atrial fibrillation. Circ. Res. 97, 629-636 (2005).
148. Shiroshita-Takeshita, A., Brundel, B. J. J. M., Lavoie, J. & Nattel, S. Prednisone prevents atrial fibrillation promotion by atrial tachycardia remodeling in dogs. Cardiovasc. Res. 69, 865-875 (2006).
149. Dernellis, J. & Panaretou, M. Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation. Eur. Heart J. 25, 1100-1107 (2004).
150. Shiroshita-Takeshita, A., Schram, G., Lavoie, J. & Nattel, S. The effect of simvastatin and antioxidant vitamins on atrial fibrillation-promotion by atrial tachycardia remodeling in dogs. Circulation 110, 2313-2319 (2004).
151. Wijffels, M. C. et al: Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 92, 1954-1968 (1995).
152. Shinagawa, K., Shiroshita-Takeshita, A., Schram, G. & Nattel, S. Effects of antiarrhythmic drugs on fibrillation in the remodeled atrium: Insights into the mechanism of the superior efficacy of amiodarone. Circulation 107, 1440-1446 (2003).
153. 2+ channel blocker mibefradil prevents the development of a substrate for atrial fibrillation by tachycardia-induced atrial remodeling in dogs. Circulation 100, 2191-2197 (1999).
154. Matsumoto, Y. et al. Long-term endothelin a receptor blockade inhibits electrical remodeling in cardiomyopathic hamsters. Circulation 106, 613-619 (2002).
155. Wang, Q. et al. Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias. Nature Genet. 12, 17-23 (1996).
156. Curran, M. E. et al. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome, Cell 80, 795-803 (1995).
157. Bennett, PB., Yazawa, K. & Makita, N. Molecular mechanism for an inherited cardiac arrhythmia. Nature 376, 683-685 (1995).
158. Mohler, P. J. et al. Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death. Nature 421, 634-639 (2003).
159. Splawski, I., Tristani-Firouzi, M., Lehmann, M. H., Sanguinetti, M. C. & Keating, M. T. Mutations in the hminK gene cause long QT syndrome and suppress I(Ks) function. Nature Genet. 17, 338-340 (1997).
160. Abbott, G. W. et al. MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell 97, 175-187 (1999).
161. Plaster, N. M. et al. Mutations in Kir2.1 cause the developmental and episodic electrical phenotypes of Andersen's syndrome. Cell 105, 511-519 (2001).
162. Splawski, I. et al. Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell 119, 19-31 (2004).
163. Neyroud, N. et al. A novel mutation in the potassium channel gene KVLQT1 causes the Jervell and Lange-Nielsen cardioauditory syndrome. Nature Genet. 15, 186-189 (1997).
164. Schulze-Bahr, E. et al. KCNE1 mutations cause Jervell and Lange-Nielsen syndrome. Nature Genet. 17, 267-268 (1997).
165. Brugada, R., Hong, K. & Dumaine, R. Sudden death associated with short-QT syndrome linked to mutations in HERG. Circulation 109, 30-35 (2004).
166. Bellocq, C. et al. Mutation in the KCNQ1 gene leading to the short QT-interval syndrome. Circulation 109, 2394-2397 (2004).
167. Priori, S. G. et al. A novel form of short QT syndrome (SQT3) is caused by a mutation in the KCNJ2 gene. Circ. Res. 96, 800-807 (2005).
168. Chen, Q. et al. Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature 392, 293-296 (1998).
169. Priori, S. G. et al. Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation 103, 196-200 (2001).
170. Viatchenko-Karpinski, S. et al. Abnormal calcium signaling and sudden cardiac death associated with mutation of calsequestrin. Circ. Res. 94, 471-477 (2004).
171. Schulze-Bahr, E. et al. Pacemaker channel dysfunction in a patient with sinus node disease. J. Clin. Invest. 111, 1537-1545 (2003).
172. Benson, D. W. et al. Congenital sick sinus syndrome caused by recessive mutations in the cardiac sodium channel gene (SCN5A). J. Clin. Invest. 112, 1019-1028 (2003).
173. Schott, J. J. et al. Cardiac conduction defects associate with mutations in SCN5A. Nature Genet. 23, 20-21 (1999).
174. Chen, Y. H. et al. KCNQ1 gain-of-function mutation in familial atrial fibrillation. Science 299, 251-254 (2003).
175. Yang, Y. et al. Identification of a KCNE2 gain-of-function mutation in patients with familial atrial fibrillation. Am. J. Hum. Genet. 75, 899-905 (2004).
176. Xia, M. et al. A Kir2.1 gain-of-function mutation underlies familial atrial fibrillation. Biochem. Biophys. Res. Commun. 332, 1012-1019 (2005).
177. Hong, K., Bjerregaard, P., Gussak, I. & Brugada, R. Short QT syndrome and atrial fibrillation caused by mutation in KCNH2. J. Cardiovasc. Electrophysiol. 4, 394-396 (2005).
178. Hashimoto, N. et al. A novel IKACh channel blocker, NIP-151, terminates atrial fibrillation with atrial specific effective refractory period prolongation. Circulation 112, Abs II-191 (2005).